Table 1 The characteristic of included studies
From: Bleeding risks with novel oral anticoagulants especially rivaroxaban versus aspirin: a meta-analysis
Study | Year | Intervention | Dosage of intervention | Control | Dosage of control | Indication | Follow-up time (months) | Age (years) | Male (%) | BMI (kg/m2) | DM (%) | Previous stroke (%) | Hypertension (%) | Outcomes* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
COMPASS | 2017 | Rivaroxaban | 10 mg daily | Aspirin | 100 mg daily | stable ASCVD | 23 | 68.2 | 78.3 | 28.3 | 37.8 | 3.8 | 75.2 | 1,2,3,4 |
NAVIGATE-ESUS | 2018 | Rivaroxaban | 15 mg daily | Aspirin | 100 mg daily | ESUS | 11 | 66.9 | 61.5 | 27.2 | 25 | 17.5 | 77.4 | 1,2,3,4 |
EINSTEIN CHOICE | 2017 | Rivaroxaban | 10 mg daily | Aspirin | 100 mg daily | VTE treatment | 12 | 58.8 | 55.9 | NA | NA | NA | NA | 1,2,3,4 |
EINSTEIN CHOICE | 2017 | Rivaroxaban | 20 mg daily | Aspirin | 100 mg daily | VTE treatment | 12 | 58.4 | 55.6 | NA | NA | NA | NA | 1,2,3,4 |
GEMINI-ACS-1 | 2017 | Rivaroxaban | 5 mg daily | Aspirin | 100 mg daily | ACS | 10.8 | 62 | 75 | NA | 30 | NA | 73 | 1,2,3 |
EPCAT II | 2018 | Rivaroxaban | 10 mg daily | Aspirin | 81 mg daily | VTE prophylaxis | 3 | 62.8 | 47.8 | 31 | NA | NA | NA | 1 |
Ren et al | 2021 | Rivaroxaban | 10 mg daily | Aspirin | 200 mg daily | VTE prophylaxis | 3 | 52.3 | 34.3 | 23.5 | 5.7 | NA | 15.7 | 1,2,3,4 |
Zou et al | 2014 | Rivaroxaban | 10 mg daily | Aspirin | 100 mg daily | VTE prophylaxis | 1 | 63.1 | 28.3 | 27.7 | NA | NA | NA | 1,2,3,4 |
AVERROES | 2011 | Apixaban | 10 mg daily | Aspirin | 81-324 mg daily | AF | 13.2 | 70 | 58.5 | 28 | 19.6 | 13.6 | 86.3 | 1,2,3,4 |
RE-SPECT ESUS | 2019 | Dabigatran | 220/300 mg daily | Aspirin | 100 mg daily | ESUS | 19 | 64.2 | 63.1 | 27.2 | 22.7 | 18.1 | 73.9 | 1,2,3,4 |
DATAS II | 2020 | Dabigatran | 220/300 mg daily | Aspirin | 81 mg daily | ANIS | 3 | 66.6 | 61.6 | NA | 23.6 | 23.3 | 57.1 | 1 |